Menu Search
Equities

Shanghai Henlius Biotech Inc

SGBCF:PKC

Shanghai Henlius Biotech Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded68.75k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 25 2024 13:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Henlius Biotech Inc grew revenues 67.82% from 3.21bn to 5.39bn while net income improved from a loss of 695.26m to a gain of 546.02m.
Gross margin73.23%
Net profit margin12.27%
Operating margin14.90%
Return on assets7.07%
Return on equity30.99%
Return on investment14.25%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Henlius Biotech Inc increased its cash reserves by 28.83%, or 194.19m. The company earned 1.05bn from its operations for a Cash Flow Margin of 19.42%. In addition the company generated 144.43m cash from financing while 1.00bn was spent on investing.
Cash flow per share2.12
Price/Cash flow per share9.88
Book value per share5.16
Tangible book value per share-4.49
More ▼

Balance sheet in CNYView more

Shanghai Henlius Biotech Inc has a Debt to Total Capital ratio of 61.13%, a lower figure than the previous year's 62.37%.
Current ratio0.4888
Quick ratio0.329
Total debt/total equity1.57
Total debt/total capital0.6113
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.